PET/CT in pediatric oncology

Indian Journal of Cancer

Volumn 47, Issue 4, 2010, Pages 360-370

  Samuel, A M ^a  

^a Functional Imaging and Research Centre ^*  (India)

Author keywords

PET CT pediatric oncology

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; RADIOISOTOPE;

ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLADDER CATHETERIZATION; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; BONE TUMOR; BRAIN TUMOR; BROWN ADIPOSE TISSUE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; ECHOGRAPHY; ENDOCRINE TUMOR; ESOPHAGITIS; EWING SARCOMA; HEPATOBLASTOMA; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMAGING; IMMOBILIZATION; INFLAMMATION; ISOTOPE LABELING; METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEUROBLASTOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE TECHNICIAN; OSTEOSARCOMA; PHARYNGITIS; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY; SCINTISCANNING; SEDATION; SOFT TISSUE SARCOMA; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THYROID CARCINOMA; TUMOR GROWTH; TUMOR RECURRENCE; WHITE ADIPOSE TISSUE;

CHILD; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78650104082     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.73551     Document Type: Conference Paper

References (43)

1. American Academy of Pediatrics, Committee on Drugs: Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Pediatrics 1992;89:1110-5.
2. American Society of Anesthesiologists, Task Force on Sedation and Analgesia by Non-Anesthesiologists: Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002;96:1004-17.
3. Cohade C, Osman M, Pannu HK, Wahl RL. Uptake in supraclavicular area fat ("USA-Fat"): description on 18 F-FDG PET/CT. J Nucl Med 2003;44:1760-4.
4. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging 2002;29:1393-8.
5. Yeung HW, Grewal RK, Gonen M, Schoder H, Larson SM. Patterns of [18]F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003;44:1789-96.
6. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16:173-80.
7. Torrente J, Spottswood S, Seekins J, Delbeke D. PET/low-dose CT versus diagnostic CT in the follow-up of pediatric patients with lymphoma Nucl Med 2007;48:118.
8. Beker DB, Berrak SG, Canpolat C, Tugtepe H, Ones T, Tecimer T. Falsepositivity of FDG-PET/CT in a child with Hodgkin disease. Pediatr Blood Cancer 2008;50:881-3.
9. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005;25:191-207.
10. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18 F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18 F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-9.
11. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18 F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33.
12. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43:1018-27.
13. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's lymphoma: comparison with CT. Leuk Lymphoma 2000;39:543-53.
14. Weihrauch MR, Re D, Scheidhauer K, Ansn S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18 F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930-4.
15. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43:1018-27.
16. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's lymphoma: comparison with CT. Leuk Lymphoma 2000;39:543-53.
17. Weihrauch MR, Re D, Scheidhauer K, Ansn S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18 F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930-4.
18. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
19. Rmer W, Hanauske AR, Ziegler S, Thdtmann R, Weber W, Fuchs C, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-71.
20. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Persistent tumor 18 F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000;85:613-8.
21. Hoekstra OS, Ossenkoppele GJ, Golding R, van Lingen A, Visser GW, Teule GJ, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993;34:1706-10.
22. Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G, et al. Positron emission tomography with [18 F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002;16:260-7.
23. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28.
24. Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med 2000;41:999-1005.
25. Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123-30.
26. McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the Evaluation of Childhood Sarcomas. AJR 2005;184:1293-304.
27. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy- D-glucosecompared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199:743-50.
28. Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 1996;37:16-21.
29. Shulkin BL, Wieland DM, Castle VP. Carbon-11 epinephrine PET imaging of neuroblastoma. J Nucl Med 1999;40:129.
30. Franzius C, Hermann K, Weckesser M, Kopka K, Juergens KU, Vormoor J, et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic system: Feasibility study and comparison with 123I-MIBG SPECT-CT. J Nucl Med 2006;47:1635-42.
31. Franzius C, Sciuk J, Daldrup-Link HE, Jrgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumors: Comparison with bone scintigraphy. Eur J Nucl Med 2000;27:1305-11.
32. Kneisl JS, Patt JC, Johnson JC, Zuger JH. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas? Clin Orthop Relat Res 2006;450:101-04.
33. Hoh CK, Hawkins RA, Dahlbom M, Glaspy JA, Seeger LL, Choi Y, et al. Whole body skeletal imaging with [18 F] fluoride ion and PET. J Comput Assist Tomogr 1993;17:34-41.
34. Tse N, Hoh C, Hawkins R, Phelps M, Glaspy J. Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma. Am J Clin Oncol 1994;17:22-25.
35. Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, Ribeiro RC. Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatr Blood Cancer 2005;45:265-73.
36. Roebuck DJ, Perilongo G. Hepatoblastoma: an oncological review. Pediatr Radiol 2006;36:183-6.
37. Mody RJ, Pohlen JA, Malde S, Strouse PJ, Shulkin BL. FDG-PET for the study of primary hepatic malignancies in children. Pediatr Blood Cancer 2006;47:51-4.
38. Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: A report of 103 consecutive procedures. J Neurosurg 2006;104:238-53.
39. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK. Use of [18 F] fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33:540-8.
40. Rozental JM, Levine RL, Nickles RJ. Changes in glucose uptake by malignant gliomas: preliminary study of prognostic significance. J Neurooncol 1991;10:75-83.
41. Grnwald F, Klicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
42. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131 I scan. J Nucl Med 2001;42:71-76
43. Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, et al. Clinical impact of 18 F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131 I scanning results after therapy. J Nucl Med 2001;42:1464-9.